Related Experiment Video
Updated: Aug 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Erlotinib hydrochloride
John D Minna1, Jonathan Dowell
1Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas, 75390-8593, USA. john.minna@utsouthwestern.edu
Abstract:
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.
